<DOC>
	<DOCNO>NCT02768961</DOCNO>
	<brief_summary>The objective study : 1 . To perform systematic screen evaluation prevalence infection hepatitis C virus ( HCV ) , hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) prison population . 2 . To perform adequate characterization patient characteristic HCV infection population . 3 . To evaluate effectiveness security prison population interferon-free antiviral regimen . 4 . To evaluate impact strategy systematic HCV treatment rate persistent infection , reinfection super-infection prison population , short , medium long term .</brief_summary>
	<brief_title>Program Screening , Prevention Elimination Hepatitis C Penitentiary Institutions Cantabria ( JAILFREE-C )</brief_title>
	<detailed_description>Background : Infections cause hepatitis B , C HIV viruses represent serious health problem . The inmate population represent reservoir high prevalence kind infection . The completion secondary prevention early detection infection early stage , tertiary prevention treatment diagnosed case , constitute one pillars approach disease . This strategy even valuable inmate population help eliminate source spread diseases addition relieve burden disease population . In regard , one mandate recently adopt National Strategy Plan Hepatitis C Spain emphasize strategy . Finally , program nature intend pilot experience could extend prison community national European level . Endpoints 1 . - To estimate prevalence HBV , HCV HIV inmate population El Dueso . 2 . - To perform systematic treatment inmate population HCV infection . The treatment direct , prevalent population new prisoner enter prison . The detected infection also treat accordingly . 3 . - To carry descriptive evaluation efficacy safety interferon-free regimen HCV infection population . This regimen mainly base Sofosbuvir ledipasvir ( Â± RBV ) accord current clinical practice adopt National Strategy Plan Hepatitis C. 4 . - To evaluate rate persistent infection , reinfection super-infection define . Projected Study Design The present study divide two part . A transversal observational one epidemiological basis aim determine prevalence viral infection hepatitis B C virus also HIV inmate population . In second prospective phase follow-up , systematic treatment infect cohort carry accordance current clinical practice adopt National Strategy Plan Hepatitis C. Data efficacy , safety quality life collect throughout study . Finally , evaluation rate persistent infection , reinfection super-infection also record . Treatment new admission throughout study period also contemplate . Patients Methods : Patients : 1 . - Epidemiological transversal phase : 435 subject ( whole inmate population ) include . 2 . - Prospective observational phase : 120 infected patient ( take account report chronic HCV infection prevalence 20 % inmate population -data late National Strategic Plan address hepatitis C National Health Service `` NHS '' 2015- ) intend treat newly infect inmate enter prison two year study . Endpoints : Primary endpoint : Sustained Virological Response ( SVR ) 12 week end treatment . Secondary outcome : SVR 4 week , Safety issue , Quality life , Serum prevalence chronic HCV , HBV infection ; re-infection/superinfection rate ; cost-effectiveness Variables : Variables : HCV status ELISA ; Viral load ( PCR ) HCV IU / ml ( primary ) , treatment type duration , serological status HBV infection ; liver stiffness Fibroscan . QoL variable , ultrasonographic variable . phylogenetic analysis HCV genome case non-response . cost Projected Number Sites ( additional site , please specify ) 1 ( El Dueso Penitentiary Centre ) Participating Countries 1 ( Spain ) Anticipated First Patient In 2-1-2016 Projected Duration Enrollment 1 month prevalent inmate population . The entry subjets ( new inmate ) open throughout study Projected Duration Treatment 6 month ( 8-24 week accord patient virological characteristic ) . Study Duration 31 month ( 1 month enrollment + 6 month treatment + 24 month observation final evaluation reinfections )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Epidemiology study : All inmate El Dueso Penitentiary Centre include new admission within study period . Interventional study : All HCV infect patient detectable viral load ( HCV RNA ) Informed consent signature Not inform consent signature . Pregnant breastfeed woman Hypersensitivity temporary permanent absolute contraindication either drug prescribe accord clinical virological characteristic patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>sofosbuvir</keyword>
	<keyword>ledipasvir</keyword>
	<keyword>ribavirin</keyword>
	<keyword>prisoner</keyword>
	<keyword>hepatitis c</keyword>
	<keyword>prevalence</keyword>
	<keyword>hepatitis b</keyword>
</DOC>